Cohort 3 for Prostate Cancer

"There are currently 26 independent trials studying MGC018 with 3 of them being Phase 3 clinical trials. Most studies are based in A CORU�A and Virginia; however, there are 810 total sites running these investigations."

"MGC018 has been under investigation since 2016. The first clinical trial, sponsored by Incyte Corporation concluded that same year. After the successful Phase 1 drug approval in 2016, there are now 26 active MGC018 studies being conducted in 117 cities and 43 countries."

"According to the listing on clinicaltrials.gov, this trial is no longer actively recruiting patients. The study was first posted on 11/21/2018 and has not been updated since 11/2/2022. Even though this particular trial is not taking any more participants, there are 2180 other trials currently enrolling patients."

"The primary outcome of this study, which will be assessed over the course of 24 months, is the number of patients experiencing adverse events while taking MGC018. This will be measured using CTCAE v4.03. Secondary outcomes include the area under the curve for plasma concentration versus time curves of vobramitamab duocarmazine and vobramitamab duocarmazine+retifanlimab, overall survival rate of MGC018 efficacy as best overall response rate using RECIST v1.1, and objective response rate of vobramitamab duocarmazine defined as the number"

"This particular study is not recruiting patients at the moment, having last updated their posting on November 2nd, 2022. There are, however, 26 other trials related to MGC018 and 2154 studies concerning oral squamous cell carcinoma that are currently looking for participants."

"At the moment, there are 8 different hospitals conducting this clinical trial. If you live near Fairfax, Washington or Las Vegas, please consider enrolling as these will minimize travel time and effort."